PerkinElmer, Inc. (PKI) and Cerep, Inc. Announce Expansion of New Kinase Assay Offerings to Accelerate Drug Candidate Screening and Validation
4/28/2009 10:08:44 AM
LILLE, France--(BUSINESS WIRE)--At the 15th Annual Society for Biomolecular Sciences (SBS) Conference today, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, and Cerep SA, a leading provider of drug candidate screening and profiling technologies, announced the expansion of their kinase assay offering. Close to 200 new kinase assays validated with PerkinElmer’s LANCE® UltraTM technology will be offered for use through Cerep’s drug candidates selection and qualification services.
comments powered by